Nothing Special   »   [go: up one dir, main page]

PT1039892E - Utilizacao de acidos gordos polinsaturados para reducao da incidencia de enterocolite necrotizante - Google Patents

Utilizacao de acidos gordos polinsaturados para reducao da incidencia de enterocolite necrotizante

Info

Publication number
PT1039892E
PT1039892E PT98906580T PT98906580T PT1039892E PT 1039892 E PT1039892 E PT 1039892E PT 98906580 T PT98906580 T PT 98906580T PT 98906580 T PT98906580 T PT 98906580T PT 1039892 E PT1039892 E PT 1039892E
Authority
PT
Portugal
Prior art keywords
incidence
reducing
fatty acids
necrotizing
polyesaturated
Prior art date
Application number
PT98906580T
Other languages
English (en)
Inventor
Susan E Carlson
Michael B Montalto
Margaret H Dohnalek
John D Benson
David A Borror
David V Diodato
Debra L Ponder
Original Assignee
Abbott Lab
Univ Tennessee Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1039892(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/943,576 external-priority patent/US6080787A/en
Application filed by Abbott Lab, Univ Tennessee Res Foundation filed Critical Abbott Lab
Publication of PT1039892E publication Critical patent/PT1039892E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
PT98906580T 1997-02-21 1998-02-19 Utilizacao de acidos gordos polinsaturados para reducao da incidencia de enterocolite necrotizante PT1039892E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis

Publications (1)

Publication Number Publication Date
PT1039892E true PT1039892E (pt) 2004-09-30

Family

ID=27420004

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98906580T PT1039892E (pt) 1997-02-21 1998-02-19 Utilizacao de acidos gordos polinsaturados para reducao da incidencia de enterocolite necrotizante

Country Status (24)

Country Link
US (1) US6306908B1 (pt)
EP (1) EP1039892B1 (pt)
JP (1) JP2001516343A (pt)
CN (1) CN1200701C (pt)
AT (1) ATE265207T1 (pt)
AU (1) AU732903B2 (pt)
BR (1) BR9807443A (pt)
CA (1) CA2281706C (pt)
DE (1) DE69823548T2 (pt)
DK (1) DK1039892T3 (pt)
ES (1) ES2219871T3 (pt)
HK (1) HK1034033A1 (pt)
HU (1) HUP0300236A3 (pt)
ID (1) ID22744A (pt)
IL (1) IL131126A (pt)
NO (1) NO994052L (pt)
NZ (1) NZ337039A (pt)
PL (1) PL343902A1 (pt)
PT (1) PT1039892E (pt)
RU (1) RU2199317C2 (pt)
SK (1) SK112399A3 (pt)
TR (1) TR199902023T2 (pt)
TW (1) TWI230607B (pt)
WO (1) WO1998036745A2 (pt)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
US20090274660A1 (en) * 1999-08-17 2009-11-05 Immunopath Profile, Inc. Pluripotent therapeutic compositions and uses thereof
US6596302B2 (en) 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
CN100418519C (zh) * 2002-09-24 2008-09-17 三得利株式会社 用于增强认知能力的含有花生四烯酸或其与二十二碳六烯酸的组合的组合物
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CN1838888B (zh) * 2003-06-23 2016-02-17 雀巢技术公司 婴儿或第二阶段配方奶
EP1643862A1 (en) * 2003-06-24 2006-04-12 University of Kansas Medical Center Infant formula
GB2422373B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
EP1597978A1 (en) * 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
JP5301155B2 (ja) * 2004-06-22 2013-09-25 エヌ．ブイ．・ヌートリシア Ｈｉｖ患者における、障壁の完全性の改善
EP1721611A1 (en) * 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1656839A1 (en) 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
CA2605960A1 (en) * 2005-04-21 2006-10-26 N.V. Nutricia Nutritional supplement for hiv patients
CN105663151A (zh) 2005-05-23 2016-06-15 麻省理工学院 含有多不饱和脂肪酸的组合物及其使用方法
JP2007063219A (ja) * 2005-09-01 2007-03-15 Juntendo 新生児壊死性腸炎疾患予防剤
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
WO2007059431A1 (en) 2005-11-14 2007-05-24 The Trustees Of Columbia University In The City Of New York Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
CN103054048B (zh) * 2005-12-23 2014-11-19 纽崔西亚公司 用于预防肥胖症的婴儿营养组合物
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US20080003330A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
US7867542B2 (en) * 2006-11-02 2011-01-11 Ach Food Companies, Inc. Non-flammable release composition
WO2009039101A1 (en) 2007-09-17 2009-03-26 Cornell University Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
CN101896073B (zh) * 2007-10-09 2013-11-20 酶学技术有限公司 用于治疗胃肠道紊乱和促进肠道发育及成熟的脂质组合物
UY31410A1 (es) * 2007-10-30 2009-05-29 Composicion que comprende acidos grasos poliinsaturados y carbon vegetal activado
MX2010004820A (es) 2007-11-01 2010-08-10 Enzymotec Ltd Mezcla lipidica para nutricion infantil.
US8361534B2 (en) * 2007-12-20 2013-01-29 Abbott Laboratories Stable nutritional powder
CN101951789B (zh) 2007-12-20 2014-02-05 雅培制药有限公司 稳定的营养粉
EP2100897A1 (en) 2008-01-30 2009-09-16 BNLfood Investments SARL Lecithin based composition and its use in food
WO2009096772A1 (en) * 2008-02-01 2009-08-06 N.V. Nutricia Composition for stimulating natural killer cell activity
US9737213B1 (en) * 2009-03-24 2017-08-22 Vioptix, Inc. Using an oximeter probe to detect intestinal ischemia
RU2559646C2 (ru) * 2009-04-01 2015-08-10 Нестек С.А. Снижение риска ожирения
TW201112967A (en) 2009-09-16 2011-04-16 Abbott Lab Dryblended nutritional powders
TW201121431A (en) 2009-12-01 2011-07-01 Abbott Lab Soy protein-based nutritional formula with superior stability
TWI492744B (zh) 2009-12-04 2015-07-21 Abbott Lab 使用類胡蘿蔔素調節早產兒發炎症之方法
AU2010329990B2 (en) * 2009-12-08 2015-07-16 Nestec S.A. Infant formula with probiotics and milk fat globule membrane components
BR112012017978A2 (pt) * 2010-01-19 2016-05-03 Abbott Lab fórmulas nutricionais contendo simbióticos
MX2012008785A (es) 2010-01-29 2012-08-17 Abbott Lab Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbut irato (hmb) de calcio.
CA2785523A1 (en) 2010-01-29 2011-08-04 Abbott Laboratories Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP2397038A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Early programming of brain function through soy protein feeding
WO2012009426A1 (en) 2010-07-13 2012-01-19 Abbott Laboratories High tolerance infant formula including hydrolyzed protein
EP2422629A1 (en) 2010-08-23 2012-02-29 Abbott Laboratories Methods for enhancing cognition and/or memory using maltodextrins
EP2984941A1 (en) 2010-08-24 2016-02-17 Abbott Laboratories Nutritional products having improved organoleptic properties
WO2012027287A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Nutritional products including pea protein hydrolysates
US20120172445A1 (en) 2010-12-29 2012-07-05 Abbott Laboratories Nutritional products including a novel fat system including fatty acids
SG191797A1 (en) 2010-12-31 2013-08-30 Abbott Lab Methods of using human milk oligosaccharides for improving airway respiratory health
MX355780B (es) 2010-12-31 2018-04-30 Abbott Lab Fórmula pediátrica sintética para estimular células nerviosas entéricas en el tracto gastrointestinal.
CN103763940B (zh) 2010-12-31 2015-10-14 雅培制药有限公司 促进有益微生物群生长的益生菌和人乳寡糖的合益素组合
WO2012092156A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
MX338174B (es) 2010-12-31 2016-04-06 Abbott Lab Metodos para reducir la incidencia de la tension oxidativa al usar los oligosacaridos de leche humana, la vitamina c y los agentes antiinflamatorios.
ES2719404T5 (es) 2010-12-31 2024-09-18 Abbott Lab Composiciones nutricionales que comprenden oligosacáridos de leche humana para el uso en el tratamiento y/o prevención de la infección por rotavirus entérico
NZ612105A (en) 2010-12-31 2015-02-27 Abbott Lab Human milk oligosaccharides for modulating inflammation
CN108420076A (zh) 2010-12-31 2018-08-21 雅培制药有限公司 包含人乳低聚糖和长链多不饱和脂肪酸的营养型制剂以及其用途
WO2013012989A2 (en) 2011-07-19 2013-01-24 The Trustees Of Columbia University In The City Of New York Method and system for production of hydrogen and carbon monoxide
DK2734210T3 (en) 2011-07-22 2018-01-22 Abbott Lab GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
WO2013032674A1 (en) 2011-08-29 2013-03-07 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
SG11201403693SA (en) 2011-12-29 2014-07-30 Abbott Lab Methods for reducing microbial contamination of dryblended powdered nutritional compositions
WO2013101516A1 (en) 2011-12-29 2013-07-04 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using extracted genomic dna
WO2013148134A1 (en) 2012-03-27 2013-10-03 Abbott Laboratories Methods for modulating cell-mediated immunity using human milk oligosaccharides
WO2013170189A1 (en) 2012-05-11 2013-11-14 Abbott Laboratories Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
EP2708145B1 (en) 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
EP3704957A1 (en) 2012-09-14 2020-09-09 Abbott Laboratories Methods for increasing brain functionality using 2-fucosyl-lactose
EP2708146A1 (en) 2012-09-17 2014-03-19 Abbott Laboratories, Inc. Nutritional composition for pregnant women with a beneficial glucose and insulin profile
WO2014078544A1 (en) 2012-11-14 2014-05-22 Abbott Laboratories Compositions and methods for improving the long term safety of powdered infant formulas
WO2014099904A1 (en) 2012-12-17 2014-06-26 Abbott Laboratories Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject
CA2893217C (en) 2012-12-18 2017-11-28 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
EP2745705A1 (en) 2012-12-18 2014-06-25 Abbott Laboratories Nutritional use of human milk oligosaccharides
WO2014100022A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Dietary oligosaccharides to enhance learning and memory
EP3469912A1 (en) 2012-12-20 2019-04-17 Abbott Laboratories Nutritional formulations using human milk oligosaccharides for modulating inflammation
EP2745708A1 (en) 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
CN105188416A (zh) 2013-03-12 2015-12-23 雅培制药有限公司 包含多功能粘度调节剂的组合物
CA2903565A1 (en) 2013-03-15 2014-09-18 Abbott Laboratories Methods of maintaining and improving muscle function using epigallocatechin-3-gallate
EP2986163B1 (en) 2013-03-15 2017-04-19 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
CN105263321B (zh) 2013-03-28 2018-07-27 哥伦比亚大学纽约管理委员会 用omega-3甘油酯再灌注促进对用于移植的供体器官的保护
MX2015017056A (es) 2013-06-10 2016-04-13 Abbott Lab Metodos y composiciones para incrementar el desempeño cognitivo.
WO2015048646A1 (en) 2013-09-30 2015-04-02 Abbott Laboratories Protein powder
MX2015003499A (es) 2013-10-11 2015-07-10 Abbott Lab Composicion mutricional para mujeres embarazadas con un perfil de glucosa e insulina benefico.
CN103558296B (zh) * 2013-10-18 2015-03-04 中国农业大学 一种基于脂肪酸检测的动物源性饲料原料鉴别方法
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
US10568896B2 (en) 2013-11-19 2020-02-25 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (en) 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
WO2015105981A2 (en) 2014-01-09 2015-07-16 Abbott Laboratories Conditional essentiality of hmb
SG11201608248YA (en) 2014-04-08 2016-10-28 Abbott Lab Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
DE102015101273A1 (de) * 2015-01-29 2016-08-04 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
RU2665947C1 (ru) * 2017-07-13 2018-09-05 Атикат Магомедхановна Герейханова Способ лечения некротического энтероколита
WO2020247225A1 (en) 2019-06-07 2020-12-10 Abbott Laboratories Nutritional ingredient with flow and antifoam properties
US20230149542A1 (en) 2020-04-06 2023-05-18 Abbott Laboratories Nutritional formulations for modulating respiratory-induced cytokines
CN112137998A (zh) * 2020-10-10 2020-12-29 上海交通大学医学院附属新华医院 一种活性成分在制备防治坏死性小肠结肠炎药物中的应用
WO2022177965A1 (en) 2021-02-16 2022-08-25 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2022226311A1 (en) 2021-04-23 2022-10-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function
WO2022266058A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods and compositions for treating gas
WO2023159093A1 (en) 2022-02-16 2023-08-24 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2024064327A1 (en) 2022-09-22 2024-03-28 Abbott Laboratories Human milk oligosaccharides for enhancing blood-brain barrier function

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092121B1 (en) 1982-04-12 1987-12-16 Board Of Regents, The University Of Texas System Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en) 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US4950656A (en) 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5032585A (en) 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US5043329A (en) 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5000975A (en) 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5116819A (en) * 1989-05-05 1992-05-26 Clintec Nutrition Co. Enteral diet for patients with pulmonary disease
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
ATE200619T1 (de) 1991-01-24 2001-05-15 Martek Corp Mikrobielle öle und ihre verwendungen
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
DE4407939A1 (de) * 1993-03-15 1994-09-22 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von fett- und cholesterinreduzierten pulverförmigen Produkten auf Eibasis
FR2721481B1 (fr) * 1994-06-27 1996-09-06 Inst Rech Biolog Sa Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
DE59502779D1 (de) 1994-10-05 1998-08-13 Milupa Gmbh & Co Kg Phospholipidhaltige fettmischung mit lcp-fettsäuren
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品
US5917068A (en) 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US5790138A (en) 1996-01-16 1998-08-04 Monolithic System Technology, Inc. Method and structure for improving display data bandwidth in a unified memory architecture system

Also Published As

Publication number Publication date
TWI230607B (en) 2005-04-11
CA2281706C (en) 2008-08-05
NZ337039A (en) 2001-06-29
NO994052L (no) 1999-10-20
ID22744A (id) 1999-12-09
DE69823548T2 (de) 2005-02-24
EP1039892B1 (en) 2004-04-28
HUP0300236A3 (en) 2003-09-29
RU2199317C2 (ru) 2003-02-27
NO994052D0 (no) 1999-08-23
AU732903B2 (en) 2001-05-03
US6306908B1 (en) 2001-10-23
TR199902023T2 (xx) 2001-09-21
EP1039892A2 (en) 2000-10-04
JP2001516343A (ja) 2001-09-25
ATE265207T1 (de) 2004-05-15
WO1998036745A3 (en) 2002-10-03
HUP0300236A2 (hu) 2003-06-28
CA2281706A1 (en) 1998-08-27
SK112399A3 (en) 2000-12-11
WO1998036745A2 (en) 1998-08-27
HK1034033A1 (en) 2001-10-12
IL131126A0 (en) 2001-01-28
DE69823548D1 (de) 2004-06-03
PL343902A1 (en) 2001-09-10
AU6176998A (en) 1998-09-09
CN1269718A (zh) 2000-10-11
IL131126A (en) 2003-04-10
DK1039892T3 (da) 2004-08-30
CN1200701C (zh) 2005-05-11
BR9807443A (pt) 2000-04-25
ES2219871T3 (es) 2004-12-01

Similar Documents

Publication Publication Date Title
PT1039892E (pt) Utilizacao de acidos gordos polinsaturados para reducao da incidencia de enterocolite necrotizante
Vidgren et al. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
Calder Immunomodulation by omega-3 fatty acids
PT843972E (pt) Composicao nutritiva que inclui gorduras para o tratamento do sindrome metabolico
DK1121115T3 (da) PUFA-tilskud
EP2255668A3 (en) Production and Use of a Polar Lipid-Rich Fraction Containing Omega-3 and/or Omega-6 Highly Unsaturated Fatty Acids from Microbes, Genetically Modified Plant Seeds and Marine Organisms
PL190841B1 (pl) Syntetyczna kompozycja lipidowa i jej zastosowanie do wytwarzania pokarmu dla niemowląt
BR0207907A (pt) Ëleo contendo um ou mais ácidos graxos poliinsaturados de cadeia longa derivados de biomassa, seu processo de preparação, composição farmacêutica ou cosmética, nutricional ou de gênero alimentìcio contendo o mesmo
MX2008014264A (es) Esteres de glicerol estructurados utiles como barreras de humedad comestibles.
JP2021137035A5 (ja) 高度不飽和脂肪酸のトリグリセリドを含む組成物
CO5550401A2 (es) Mezclas lipidas y productos alimenticios que contienen acido graso oleico y acidos grasos omega-6 diseñados para aumentar el nivel de lipido intramiocelular
DK1027831T3 (da) Stabiliseret fedtstofsammensætning, fremgangsmåde til fremstilling deraf og ernæringsprodukt indeholdende denne
ATE454820T1 (de) Neuartige fettpulver
OGUNLEIYE et al. Effect of fish oil and safflower oil in common Japanese diet on human plasma fatty acid composition
Lawrence Effect of dietary lipids on adjuvant-induced arthritis in rats
Sandoval et al. Omega-3 in the Prevention of Cardiovascular Diseases
Renuka et al. EFFECT OF OMEGA 3 FATTY ACID IN PERIODONTITIS
Nettleton Omega-3 and Omega-6 Polyunsaturated Fatty Acids in the American Diet.
TH53682A (th) น้ำมันที่มีกรดไขมันที่มีหลายพันธะไม่อิ่มตัวชนิดโซ่ยาวหนึ่งชนิดหรือมากกว่าที่ได้มาจากมวลชีวภาพ กรรมวิธีสำหรับการเตรียมมัน โภชนาหารหรือโภชนาการ เครื่องสำอางหรือสารผสมทางเภสัชกรรมที่มีมัน